President Donald Trump is still looking to keep the pressure on pharmaceutical companies in an effort to keep U.S. drug prices down, but some drugmakers are moving forward with price increases.
Pharmaphorum reports several drugmakers, including Pfizer, Allergan and AbbVie, are hiking prices to ring in 2019. According to the report, Allergan raised the prices of more than 50 drugs in its portfolio, more than half of which saw a 9.5 percent increase.
Pfizer Chairman and CEO Ian Read said the key to avoid clearing out consumers’ wallets is to target out-of-pocket costs.
“We believe the best means to address affordability of medicines is to reduce the growing out-of-pocket costs that consumers are facing due to high deductibles and co-insurance, and ensure that patients receive the benefits of rebates at the pharmacy counter,” Read said.
To read the full report on pharmaphorum, click here.
